Back to results
US 2022/0024912 A1Published application
Compounds for treatment of cancer
AssigneesOncternal Therapeutics, Inc., University of Tennessee Research Foundation
InventorsWei LI, Min XIAO, James DALTON, Sunjoo AHN, Duane D. MILLER, Jin WANG
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
Claims21
A compound of Formula IX having the structure
- wherein R4 and R5 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH2CN, NH2, hydroxyl, —(CH2)iNHCH3, —(CH2)iNH2, —(CH2)iN(CH3)2, —OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O— alkyl, C(O)H, —C(O)NH2 or NO2;
- A′ is halogen;
- substituted or unsubstituted single-, fused- or multiple-ring, aryl or (hetero)cyclic ring systems;
- substituted or unsubstituted, saturated or unsaturated N-heterocycles;
- substituted or unsubstituted, saturated or unsaturated S-heterocycles;
- substituted or unsubstituted, saturated or unsaturated O-heterocycles;
- substituted or unsubstituted, saturated or unsaturated cyclic hydrocarbons;
- or substituted or unsubstituted, saturated or unsaturated mixed heterocycles;
- wherein said A′ ring is optionally substituted by 1-5 substituents which are independently O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH2CN, NH2, hydroxyl, —(CH2)iNHCH3, —(CH2)iNH2, —(CH2)iN(CH3)2, —OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH2 or NO2;
- i is an integer between 1-5;
- and
- n is an integer between 1-3;
- or its pharmaceutically acceptable salt, hydrate, polymorph, or isomer.
10 more elements
A compound of Formula IXa having the structure
- wherein R4 and R5 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH2CN, NH2, hydroxyl, —(CH2)iNHCH3, —(CH2)iNH2, —(CH2)iN(CH3)2, —OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH2 or NO2;
- A′ is halogen;
- substituted or unsubstituted single-, fused- or multiple-ring, aryl or (hetero)cyclic ring systems;
- substituted or unsubstituted, saturated or unsaturated N-heterocycles;
- substituted or unsubstituted, saturated or unsaturated S-heterocycles;
- substituted or unsubstituted, saturated or unsaturated O-heterocycles;
- substituted or unsubstituted, saturated or unsaturated cyclic hydrocarbons;
- or substituted or unsubstituted, saturated or unsaturated mixed heterocycles;
- wherein said A′ ring is optionally substituted by 1-5 substituents which are independently O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH2CN, NH2, hydroxyl, —(CH2)iNHCH3, —(CH2)iNH2, —(CH2)iN(CH3)2, —OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH2 or NO2;
- i is an integer between 1-5;
- and
- n is an integer between 1-3;
- or its pharmaceutically acceptable salt, hydrate, polymorph, or isomer.
10 more elements
Dependencies are inferred from the claim text.